RIL
CRNX icon

Rothschild Investment LLC’s Crinetics Pharmaceuticals CRNX Stock Holding History

Rothschild Investment LLC’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.53K Buy
121
+1
+0.8% +$37 ﹤0.01% 2334
2026
Q1 		$4.36K Buy
120
+20
+20% +$893 ﹤0.01% 2129
2025
Q4 		$4.66K Hold
100
– – ﹤0.01% 1927
2025
Q3 		$4.17K Sell
100
-50
-33% -$1.6K ﹤0.01% 1786
2025
Q2 		$4.31K Buy
150
+15
+11% +$463 ﹤0.01% 1589
2025
Q1 		$4.53K Buy
135
+35
+35% +$1.31K ﹤0.01% 1485
2024
Q4 		$5.11K Buy
100
+15
+18% +$839 ﹤0.01% 1339
2024
Q3 		$4.34K Buy
85
+55
+183% +$2.84K ﹤0.01% 1353
2024
Q2 		$1.34K Buy
30
+25
+500% +$1.16K ﹤0.01% 1523
2024
Q1 		$234 Buy
+5
New +$196 ﹤0.01% 1676

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Rothschild Investment LLC's CRNX Position: Q2 2026 in Review

Rothschild Investment LLC increased its Crinetics Pharmaceuticals (CRNX) stake by 0.83% in Q2 2026, buying an estimated $37 and bringing the position to 121 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #2334.

Rothschild Investment LLC first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.11K in Q4 2024. 100 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Rothschild Investment LLC held 121 shares of Crinetics Pharmaceuticals worth $4.53K as of Q2 2026.
  • Rothschild Investment LLC bought 1 Crinetics Pharmaceuticals share in Q2 2026, an estimated $37.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2334 holding.
  • Rothschild Investment LLC first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Rothschild Investment LLC's Crinetics Pharmaceuticals position peaked at $5.11K in Q4 2024.
  • 100 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.